Objectives for Module 4: Review a brief history of HIV/AIDS policy advocacy Understand basic tactics for policy advocacy and how it differs from other kinds of advocacy Go over suggestions for developing an advocacy agenda and action plan Discuss some…
Original air date: June 6, 2017 - In November, Ministers of Health and Finance from 56 of the most high burden TB countries will gather in Moscow for the first ever Ministerial Conference on TB. This webinar provided participants with specific skills…
Original air date - MAY 30, 2017 Inadequate funding for research has contributed to programs' inability to adequately address tuberculosis (TB), the leading infectious killer in the world. The first-ever Ministerial Conference on ending TB will be held in Moscow…
March 20, 2017 – Mark Harrington, TAG's executive director, included in his keynote speech at the Critical Path to TB Drug Regimens meeting the importance of public and private sector funding for research, of thoughtful regulatory strategies, and of rapid uptake of…
This webinar featuring Kenyon Farrow, U.S. and Global Health Policy Director, presents the findings of TAG's new report, Community Mobilization: An Assessment of Mechanisms and Barriers at Community-Based and AIDS Service Organizations in Nine U.S. Metropolitan Areas. The webinar is…
On Sunday February 12, 2017 in Seattle, the AIDS Treatment Activists Coalition, AVAC, the DARE Community Advisory Board, the defeatHIV Community Advisory Board, European AIDS Treatment Group, Project Inform and TAG co-sponsored a community workshop on HIV cure research.
The first goal of the National HIV/AIDS Strategy (NHAS) is to “reduce new infections.” In order to monitor progress toward this goal, the Centers for Disease Control and Prevention (CDC) and the Office of National AIDS Policy will be looking…
On November 16, 2016, TAG held a community webinar on advocacy for TB R&D funding. This webinar builds upon TAG's annual Report on Tuberculosis Research Funding Trends to begin discussion on next steps for TB R&D funding advocacy into 2017…
July 13, 2016 The consequences of stigma among people living with and vulnerable to HIV infection are significant and far-reaching. Stigma is frequently cited as a significant barrier to successful pre-exposure prophylaxis (PrEP) awareness, access and utilization. Despite having been…
A conference call meeting initiated by HIV community advocates was held with FDA members on June 10, 2016 to discuss ways to advance the evaluation and development of products (drugs or biologics) that demonstrate promise in improving health outcomes in HIV-positive patients with inadequate immune response after long term successful HIV treatment.